|
|
|
|
|
by mlyle
2040 days ago
|
|
Trial design and trial data are shared with the FDA underway during an ordinary drug or device trial. But applications subject to FDA Fast-Track authorization processes also undergo "rolling review" where portions of the new drug application are reviewed as they are partially complete. This has narrowed the set of action items that remain. I'm sure a lot of people are staying up late as the EUA applications come in, and skimming the documents and working to identify remaining weaknesses that can be proactively addressed. But sometime in this, they need to get a good night's sleep, and begin meticulously going through the document and make sure the remaining, necessary (i.e. not waived) conditions for emergency use approval are met. |
|